Buck Institute
The Buck Institute for Research on Aging, founded in 1999 in Novato, California, is the world's first independent biomedical research institute focused solely on aging. It employs 26 faculty across 9 technology cores conducting aging biology research, clinical trials, and AI-powered healthspan platform development.
- Company typePrivate
- Founded1999
- HeadquartersNovato, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Buck Institute does
The Buck Institute for Research on Aging, founded in 1999 in Novato, California, is the first independent biomedical research institute in the world focused solely on aging. It employs 251-500 staff including 26 faculty and research professors who conduct basic, translational, and clinical research across the full spectrum of aging biology—from cellular senescence, neurodegeneration, and cancer to metabolism, mitochondrial function, and reproductive aging. The Institute operates 9 technology cores (bioinformatics, clinical research, flow cytometry, metabolomics, morphology and imaging, mouse phenotyping, proteomics and mass spectrometry, single-cell biology, and reproductive biology) and houses 5 centers and consortiums, including the Center for Human Healthspan, the Center for Healthy Aging in Women, and the USC-Buck Nathan Shock Center of Excellence.
The Institute's flagship technology is the Healthspan Horizons federated research platform, a $52 million initiative that uses responsible AI and privacy-preserving architecture to integrate genetic, clinical, microbiome, and wearable device data into personalized healthspan trajectories and earlier signals of disease risk. Other notable technologies include the BrainYears EEG-based brain age clock (developed with Sens.ai, achieving MRI-grade accuracy and a 5.18-year average brain age reduction in a 28-participant study), the N-of-1 Analyzer framework published in Cell for personalized longitudinal monitoring, the TAKEOFF multi-institutional clinical trial platform for ketone supplementation, and proprietary AI aging clock capabilities. The Institute has also incubated biotech spin-offs such as Unity Biotechnology (co-founded by Dr. Judy Campisi), the first company to test senolytics in human clinical trials.
As a 501(c)(3) nonprofit, the Buck Institute generates revenue primarily through competitive government grants (NIH, ARPA-H), private philanthropy (the Beryl Hamilton Buck Estate endowment, the Innovation Fund, President's Circle, Impact Circle, and major donors such as Nicole Shanahan), strategic partnerships and licensing, and educational programs including the nation's first PhD program in the biology of aging with USC. Its go-to-market motion is research-driven: scientific publications, conference presentations, clinical trial recruitment, public lectures, campus tours, and earned media coverage build awareness and attract collaborations with academic researchers, health systems, and commercial wellness and wearable partners such as WHOOP, Sens.ai, Nautilus Biotechnology, and the ARPA-H-funded THRIVE coalition.
Buck Institute firmographics
Firmographics- Name
- Buck Institute
- Legal name
- Buck Institute for Research on Aging
- Website
- https://buckinstitute.org
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- The Buck Institute for Research on Aging, founded in 1999 in Novato, California, is the world's first independent biomedical research institute focused solely on aging. It employs 26 faculty across 9 technology cores conducting aging biology research, clinical trials, and AI-powered healthspan platform development.
- Ownership category
- akta.pro rank
Buck Institute industry classification
Industry- Product category
- Biomedical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Buck Institute is headquartered
LocationHeadquarters
- HQ city
- Novato
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Buck Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Government Research Grants: The Buck Institute's primary revenue source comes from competitive government grants, including NIH awards. Notable grants include a $3.5 million NIH grant for the TAKEOFF clinical trial on ketone supplementation and frailty prevention, and a $2.4 million NIH grant for Alzheimer's research.
- Private Philanthropy and Donations: The Institute relies on donations to support science that adds years to people's lifespan and decades to their healthspan. Donors can give through the Buck Innovation Fund, President's Circle, Impact Circle, Planned Giving, and other designated giving areas.
- Strategic Partnerships and Licensing: Revenue generated through business development collaborations, technology licensing, and research partnerships with biotech companies and wellness organizations, including incubating companies like Unity Biotechnology.
- Educational Programs: Revenue from graduate and postdoctoral training programs, including Master's and PhD programs in partnership with USC, advanced training for scientists, and lifelong learning offerings.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels8 records
Buck Institute product offering
Product offeringCore offering
The Buck Institute for Research on Aging conducts independent biomedical research focused exclusively on the biology of aging. Its offerings include the Healthspan Horizons federated AI research platform, a portfolio of clinical trials (BETA, BIG, BIKE, GRACE, MOVE, STAK, TAKEOFF, TIME), nine shared technology cores (Bioinformatics, Proteomics, Flow Cytometry, Metabolomics, Imaging, Mouse Phenotyping, Single-cell Biology, Reproductive Biology, Clinical Research), graduate and postdoctoral training programs, and research collaborations with biotech, healthcare, and wearable technology partners.
Product overview
The Buck Institute for Research on Aging is the first independent biomedical research institute focused solely on aging research. Its primary offering is the Healthspan Horizons federated research platform, which uses AI and privacy-preserving standards to link real-world health data with biological discovery. The Institute also conducts multiple clinical trials (BETA, BIG, BIKE, GRACE, MOVE, STAK, TAKEOFF, TIME) and provides access to core technology platforms including Bioinformatics, Proteomics, Flow Cytometry, Metabolomics, and Single-cell Biology. These offerings work together to advance the understanding of the biology of aging and develop interventions to extend healthspan.
Differentiator
Problem solved
Functional benefit
Products and services
- Healthspan Horizons Platform A federated AI-driven research platform that links multi-modal real-world health data (wearables, lifestyle tracking) with deep biological measurements to generate personalized healthspan trajectories and early disease risk signals for researchers, clinicians, health systems, and wellness partners.
- Clinical Trials at the Buck A portfolio of clinical research studies including BETA, BIG, BIKE, GRACE, MOVE, STAK, TAKEOFF, and TIME studies, focusing on aging interventions, frailty prevention, exercise, nutrition, ketone supplementation, and age-related disease prevention for older adult participants and clinical research partners.
- Technology Cores Shared research technology platforms including Bioinformatics, Clinical Research Core, Flow Cytometry, Metabolomics, Morphology and Imaging, Mouse Phenotyping, Proteomics and Mass Spectrometry, Single-cell Biology, and Reproductive Biology Hub, available to internal faculty and external research collaborators.
- Graduate and Postdoctoral Training Programs Educational offerings including the USC-Buck joint PhD program in the biology of aging (launched 2014), Master's programs, postdoctoral training and fellowships, advanced training for scientists, undergraduate and postbacc training, and a Lifelong Learning program for graduate and postdoctoral trainees in aging science.
Quantifiable outcome
- Brain age reduction of 5.18 years on average over 56 days in Sens.ai collaboration study, with 85% of participants showing measurable improvement.
- +2 more outcomes
Companies that use Buck Institute
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles3 records
Buck Institute technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature8 records
Buck Institute partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major, strategic, core and minor.
- Sens.aimajorSens.ai and the Buck Institute collaborated to announce BrainYears, the first validated EEG-based biological clock that measures functional brain age with MRI-grade accuracy. A study of 28 intervention participants showed an average brain age reduction of 5.18 years over 56 days with 85% demonstrating measurable improvement. The wearable neurotechnology platform combines EEG neurofeedback, transcranial photobiomodulation, and AI-driven personalization.
- Nautilus BiotechnologystrategicNautilus Biotechnology highlighted its strategic partnership with the Buck Institute for Research on Aging at the Investor Summit. The Buck independently validated Nautilus's single-molecule proteomics platform by mapping up to 768 distinct tau proteoforms across different brain regions. Buck is also referenced as a $1.2M grant recipient from the Michael J. Fox Foundation for alpha-synuclein assay development through Nautilus's platform.
- Healthspan Horizons PartnerscoreThe Healthspan Horizons federated research platform invites participation from researchers, clinicians, health systems, and wellness partners to advance prevention-focused models of health. The initiative links multi-modal real-world data with biological discovery studies using responsible AI and privacy-preserving standards to generate interpretable healthspan trajectories.
- THRIVE Coalition (Stanford, ARPA-H)coreStanford-led coalition backed by a $34.5M ARPA-H award (PROSPR program) to develop the first FDA-grade Intrinsic Capacity score capable of predicting major health outcomes up to 20 years in advance. The Buck Institute is a coalition member contributing to the PROSPR IC score model alongside WHOOP, Methuselah Foundation, YMCA, and OpenCures.
- WHOOPmajorWHOOP partnered with Dr. Eric Verdin of the Buck Institute to develop the Healthspan with WHOOP Age feature in WHOOP 5.0 and WHOOP MG wearable devices. The devices feature next-generation health monitoring including Healthspan tracking, FDA-cleared ECG, and blood pressure monitoring, priced at $199-$359 per year.
- Unity BiotechnologycoreUnity Biotechnology was co-founded by Dr. Judy Campisi and incubates at the Buck Institute. The company develops drugs to address cellular senescence, a major driver of age-related disease, and became the first company to test senolytics in human clinical trials.
- Gladstone InstitutesstrategicCollaborating Bay Area institution alongside Buck Institute for Research on Aging and UC San Francisco on AI-driven longevity research, including the $52 million Healthspan Horizons initiative.
- UC San FranciscostrategicAcademic collaboration with UCSF including joint faculty appointments (Dr. Eric Verdin is a professor of medicine at UCSF), shared research programs, and participation in the Healthspan Horizons AI platform initiative.
- University of Southern CaliforniastrategicThe Buck and USC collaborate on the nation's first PhD program in the biology of aging (launched 2014) and the USC-Buck Nathan Shock Center of Excellence for the biology of aging research.
- Super Age GamesminorA November event in New York City developed with the Buck Institute for Research on Aging to test the eight Trainable Longevity Markers (VO2 max, grip strength, balance, agility, working memory, relational capacity, functional strength, and endurance under load) identified through peer-reviewed research.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Buck Institute competitors and assessment
Company assessmentDirect peers
- Calico Life Sciences: Alphabet-backed life sciences company focused on aging biology and longevity. Most direct competitor to Buck as a well-funded, single-purpose aging research organization pursuing basic biology to clinical translation.
- Altos Labs: Well-capitalized (>$3B raised) biotechnology company focused on cellular reprogramming and aging. Comparable in mission, talent base (Nobel laureates), and translational ambition, with greater commercial flexibility as a private company.
- Insilico Medicine: AI-driven drug discovery company applying generative AI to aging and age-related disease targets. Overlaps with Buck's Healthspan Horizons AI platform and N-of-1 analyzer framework.
- Unity Biotechnology: Buck-incubated clinical-stage biotech developing senolytics to clear senescent cells. Direct commercial counterpart translating Buck's senescence research into human trials.
- Mayo Clinic Robert and Arlene Kogod Center on Aging: Major academic aging research center within Mayo Clinic focused on geroscience and translational interventions. Comparable scale, NIH funding mix, and mission focus on age-related disease.
- Albert Einstein College of Medicine Institute for Aging Research: NIA-designated Nathan Shock Center focused on basic biology of aging with translational pipelines. Directly comparable in mission, NIH funding model, and academic geroscience leadership.
- BioAge Labs: AI-driven biotech identifying drug targets through analysis of human aging biology data. Strong overlap with Buck's Healthspan Horizons AI/data approach and clinical translation focus.
Emerging players
- Retro Biosciences: Y Combinator/Resilience-backed longevity startup pursuing cellular reprogramming and autophagy. Comparable therapeutic ambition but at earlier commercial stage than Buck's institutional pipeline.
Regional players
- Stanford Center on Longevity: Stanford-based research center focused on healthy longevity with strong overlap to Buck's Healthspan Horizons partners. Geographic peer collaborating on THRIVE coalition.
- Karolinska Institutet Center for Healthy Aging: European academic center of excellence for aging research. Comparable academic and translational research mission but serves a different geographic ecosystem.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Buck Institute social profiles
Digital presenceBuck Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Buck Institute leadership team
Management profileNumber of profiles
Profiles9 records
Buck Institute funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Buck Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Buck Institute
What does Buck Institute do?
The Buck Institute for Research on Aging conducts independent biomedical research focused exclusively on the biology of aging. Its offerings include the Healthspan Horizons federated AI research platform, a portfolio of clinical trials (BETA, BIG, BIKE, GRACE, MOVE, STAK, TAKEOFF, TIME), nine shared technology cores (Bioinformatics, Proteomics, Flow Cytometry, Metabolomics, Imaging, Mouse Phenotyping, Single-cell Biology, Reproductive Biology, Clinical Research), graduate and postdoctoral training programs, and research collaborations with biotech, healthcare, and wearable technology partners.
Is Buck Institute a public or private company?
Buck Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Buck Institute founded?
Buck Institute was founded in 1999. It employs 251 to 500 people.
Where is Buck Institute based?
Buck Institute is headquartered in Novato, United States, in the North America region.
How does Buck Institute make money?
Four revenue lines are on record. Government Research Grants are the primary driver. The others are private Philanthropy and Donations, strategic Partnerships and Licensing and educational Programs.
Who are Buck Institute's main competitors?
Direct peers on record are Calico Life Sciences, Altos Labs, Insilico Medicine, Unity Biotechnology, Mayo Clinic Robert and Arlene Kogod Center on Aging, Albert Einstein College of Medicine Institute for Aging Research and BioAge Labs. Retro Biosciences is listed as an emerging player. Regional players are Stanford Center on Longevity and Karolinska Institutet Center for Healthy Aging.
Does Buck Institute have an API?
No public API is recorded for Buck Institute.
What industry is Buck Institute in?
Buck Institute's product category is Biomedical Research Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.